Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 45257U108 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. 13G/A Amendment 2 | 17.4% |
8/14/2026
Event 6/30/2026
|
|
|
Sirenia Capital Management LP
13G/A
Amendment 1
|
4.3% |
8/14/2026
Event 6/30/2026
|
|
| Sirenia Capital Management LP | 4.3% | ||
| Alex Silverstein | 4.3% | ||
| T. Rowe Price Investment Management, Inc. 13G/A Amendment 1 | 14.5% |
5/15/2026
Event 3/31/2026
|
|
|
Redmile Group, LLC
13G/A
Amendment 4
|
4.9% |
5/15/2026
Event 3/31/2026
|
|
| Redmile Group, LLC | 4.9% | ||
| Jeremy C. Green | 4.9% | ||
|
Point72 Asset Management, L.P.
13G/A
Amendment 1
|
0% |
5/15/2026
Event 3/31/2026
|
|
| Point72 Asset Management, L.P. | 0% | ||
| Point72 Capital Advisors, Inc. | 0% | ||
| Steven A. Cohen | 0% | ||
|
Sirenia Capital Management LP
13G
|
6.1% |
5/15/2026
Event 3/31/2026
|
|
| Sirenia Capital Management LP | 6.1% | ||
| Alex Silverstein | 6.1% | ||
| Vanguard Group Inc 13G/A Amendment 3 | 0% |
3/26/2026
Event 3/13/2026
|
|
|
Redmile Group, LLC
13G/A
Amendment 3
|
5.2% |
2/17/2026
Event 12/31/2025
|
|
| Redmile Group, LLC | 5.2% | ||
| Jeremy C. Green | 5.2% | ||
|
Enavate Sciences GP, LLC
13D/A
Amendment 2
|
4.3% |
12/22/2025
Event 12/18/2025
|
|
| Enavate Sciences GP, LLC | 4.3% | ||
| Immunome Aggregator, LP | 4.3% | ||
| T. Rowe Price Investment Management, Inc. 13G | 12.2% |
11/7/2025
Event 10/31/2025
|
|
|
FMR LLC
13G/A
Amendment 1
|
15.0% |
10/7/2025
Event 9/30/2025
|
|
| FMR LLC | 15.0% | ||
| Abigail P. Johnson | 15.0% | ||
|
FMR LLC
13G
|
7.1% |
8/6/2025
Event 6/30/2025
|
|
| FMR LLC | 7.1% | ||
| Abigail P. Johnson | 7.1% | ||
| Vanguard Group Inc 13G | 5.2% |
7/29/2025
Event 6/30/2025
|
|
|
Redmile Group, LLC
13G/A
Amendment 2
|
6.2%
Checked 5% or less
|
5/15/2025
Event 3/31/2025
|
|
| Redmile Group, LLC | 6.2% | ||
| Jeremy C. Green | 6.2% | ||
| Redmile Biopharma Investments III, L.P. | 4.5% | ||
|
EcoR1 Capital, LLC
13G/A
Amendment 1
|
4.7% |
5/15/2025
Event 3/31/2025
|
|
| EcoR1 Capital, LLC | 4.7% | ||
| Oleg Nodelman | 4.7% | ||
| EcoR1 Capital Fund Qualified, L.P. | 4.4% | ||
| Janus Henderson Group PLC 13G/A Amendment 2 | 2.2% |
5/14/2025
Event 3/31/2025
|
|
|
FMR LLC
13G/A
Amendment 2
|
4.5% |
5/12/2025
Event 3/31/2025
|
|
| FMR LLC | 4.5% | ||
| Abigail P. Johnson | 4.5% | ||
| Janus Henderson Group PLC 13G/A Amendment 1 | 5.5% |
2/14/2025
Event 12/31/2024
|
|
|
Immunome Aggregator, LP
13D/A
Amendment 1
|
6.0% |
2/4/2025
Event 1/31/2025
|
|
| Immunome Aggregator, LP | 6.0% | ||
| Enavate Sciences GP, LLC | 6.0% | ||
|
Point72 Asset Management, L.P.
13G
|
5.9% |
2/3/2025
Event 1/31/2025
|
|
| Point72 Asset Management, L.P. | 5.9% | ||
| Point72 Capital Advisors, Inc. | 5.9% | ||
| Steven A. Cohen | 5.9% | ||
| Vanguard Group Inc 13G/A Amendment 2 | 4.8% |
1/30/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 5.48 k | $118 k |
| 2026 Q2 | 210 | 120 M | $2.61 B |
| 2026 Q1 | 209 | 117 M | $2.54 B |
| 2025 Q4 | 199 | 120 M | $2.57 B |
| 2025 Q3 | 164 | 91.4 M | $1.07 B |
| 2025 Q2 | 150 | 81.5 M | $758 M |
| 2025 Q1 | 152 | 77.0 M | $519 M |
| 2024 Q4 | 127 | 53.3 M | $566 M |
| 2024 Q3 | 124 | 51.7 M | $751 M |
| 2024 Q2 | 123 | 48.8 M | $591 M |
| 2024 Q1 | 113 | 37.5 M | $926 M |
| 2023 Q4 | 64 | 21.7 M | $232 M |
| 2023 Q3 | 42 | 3.10 M | $25.8 M |
| 2023 Q2 | 44 | 2.32 M | $18.3 M |
| 2023 Q1 | 34 | 1.86 M | $9.34 M |
| 2022 Q4 | 30 | 2.13 M | $4.91 M |
| 2022 Q3 | 27 | 2.39 M | $10.7 M |
| 2022 Q2 | 28 | 2.41 M | $7.78 M |
| 2022 Q1 | 34 | 3.44 M | $19.8 M |
| 2021 Q4 | 38 | 2.86 M | $37.2 M |
| 2021 Q3 | 40 | 2.39 M | $58.3 M |
| 2021 Q2 | 30 | 2.38 M | $41.1 M |
| 2021 Q1 | 32 | 1.91 M | $64.7 M |
| 2020 Q4 | 27 | 2.08 M | $20.1 M |